Rolf Ertel

Title: Rolf Ertel: Innovator in Antiarrhythmic Compounds

Introduction

Rolf Ertel is a notable inventor based in Dresden, Germany. He has made significant contributions to the field of medicinal chemistry, particularly in the development of antiarrhythmic compounds. His work has implications for the treatment of heart rhythm disorders.

Latest Patents

Rolf Ertel holds a patent for "21-Deoxydihydroajmaline derivatives." This patent describes novel 21-deoxydihydroajmaline derivatives characterized by their antiarrhythmic activity. The compounds have the formula where R and R' are each the same alkyl group of 2 to 4 carbon atoms, or R and R' together with the associated nitrogen atom form a saturated 5- or 6-atom ring. The remaining atoms are either carbon or one oxygen atom, with X representing the anion of a physiologically inorganic or organic acid.

Career Highlights

Ertel has been associated with Veb Arzneimittelwerk Dresden, where he has contributed to various research projects. His work has focused on the synthesis and application of novel pharmaceutical compounds. His innovative approach has led to advancements in the field of antiarrhythmic medications.

Collaborations

Throughout his career, Rolf Ertel has collaborated with notable colleagues, including Klaus Braun and Gunther Gabsch. These collaborations have fostered a productive research environment, leading to significant advancements in their respective fields.

Conclusion

Rolf Ertel's contributions to medicinal chemistry, particularly in the development of antiarrhythmic compounds, highlight his role as an influential inventor. His patent for 21-deoxydihydroajmaline derivatives showcases his innovative spirit and dedication to improving healthcare solutions.